Review of the Use of Pretest Probability for Molecular Testing in Non-Small Cell Lung Cancer and Overview of New Mutations That May Affect Clinical Practice

Therapeutic Advances in Medical Oncology - United States
doi 10.1177/1758834017704329
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

SAGE Publications

Related search

Molecular Testing for Stage IV Non–Small Cell Lung Cancer Patients With Targetable Mutations Following Disease Progression

Archives of Pathology and Laboratory Medicine
MedicineForensic MedicinePathologyMedical Laboratory Technology
2018English

P1.01-043 Molecular Testing for Non-Small Cell Lung Cancer in Latin American

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2017English

Programmed Death-Ligand 1 Immunohistochemistry Testing for Non-Small Cell Lung Cancer in Practice

Cancer cytopathology
Cancer ResearchOncology
2017English

Bevacizumab Combination Chemotherapy in Clinical Practice for Advanced Non-Squamous Non-Small Cell Lung Cancer

Japanese Journal of Lung Cancer
OncologyRespiratory MedicinePulmonary
2013English

Improving Molecular Testing and Personalized Medicine in Non-Small-Cell Lung Cancer in Ontario

Current Oncology
Oncology
2017English

EGFR Mutations Status for Non-Small-Cell Lung Cancer Patients

Sveikatos mokslai
2016English

P2.03-08 Molecular Spectrum of Patients With MSH2 Mutations in Chinese Non-Small Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P3.03-09 Molecular Spectrum of KIT Mutations Detection in Chinese Non-Small Cell Lung Cancer Patients

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

The Use of Expert Surrogates to Evaluate Clinical Trials in Non-Small Cell Lung Cancer

British Journal of Cancer
Cancer ResearchOncology
1987English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy